ZK-93426

ZK-93426 is a sedative and anxiolytic drug that belongs to the benzodiazepine class of medications. It was developed by the pharmaceutical company Schering AG and is known for its unique pharmacological profile.

Pharmacology

ZK-93426 is a partial agonist at the GABA_A receptor, the primary inhibitory neurotransmitter receptor in the brain. This means that it can both activate the receptor to produce a sedative effect and block the receptor to prevent the effects of other benzodiazepines. This unique pharmacological profile makes ZK-93426 less likely to cause tolerance and dependence than other benzodiazepines.

Clinical Use

ZK-93426 has been studied for its potential use in the treatment of anxiety disorders, insomnia, and alcohol withdrawal. However, it has not been widely adopted in clinical practice due to concerns about its safety and efficacy.

Side Effects

Like other benzodiazepines, ZK-93426 can cause side effects such as drowsiness, dizziness, and impaired coordination. It can also cause more serious side effects such as respiratory depression and dependence if used for extended periods of time.

See Also

• Benzodiazepine
• GABA_A receptor
• Schering AG

References

‎